Lupin Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹8,277Cr
- +32.1% YoY
- +10.7% QoQ
- Net profit
- ₹1,417Cr
- +16.1% YoY
- −3.5% QoQ
- Margin
- 30%
- +2 pp YoY
- −3 pp QoQ
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.
From Lupin's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Europe is expected to grow at a 10%-20% level, with South Africa slightly lower.
- Rest of World (ROW) markets also anticipated to continue double-digit growth.
- U.S. sales projected to return to growth trajectory from FY28, building on a base of USD 1.1-1.2 billion in FY27.
- U.S. portfolio complexity to double in 3-5 years with 50+ planned product launches including exclusive first-to-files, biosimilars, and 505(b)(2) products.
- India business growing 13.9% YoY, core prescriptions growing 15.1%, outperforming market by 1.1x, targeting 1.2x-1.3x IPM growth.
- India aims for one-third revenue from innovative products over next 10 years with 60-70 product launches.
2 more points from Lupin's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Lupin said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years.
- A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban.
- Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S.
- Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings.
2 more points from Lupin's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Lupin said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Lupin's call on order book
Create a free account to keep reading this call
Lupin — Quarterly revenue & net profit
Lupin Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 8,277 | 6,268 | +32.1% | 7,475 | +10.7% |
| Operating profit (EBITDA) | 2,450 | 1,727 | +41.9% | 2,486 | -1.4% |
| Operating margin | 30% | 28% | +2 pp | 33% | -3 pp |
| Profit before tax | 2,017 | 1,416 | +42.4% | 1,928 | +4.6% |
| Net profit (PAT) | 1,417 | 1,221 | +16.1% | 1,469 | -3.5% |
| EPS (₹) | 30.95 | 26.69 | +16% | 31.94 | -3.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹7.8K Cr, net profit ₹1.2K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lupin's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lupin and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lupin Q1 FY27 results?
Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.
What is Lupin share price analysis?
Lupin currently shows a below-average growth signal. The stock trades at a P/E of 15.1 with a market cap of ₹89,702 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lupin planning capital expenditure?
Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years. - A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban. - Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S. - Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings. - Lupin is also making manufacturing investments, such as leveraging domestic U.S.
Keep Lupin on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
